Oncology Archives - Page 2 of 23

Translating CAR-T Momentum Into Real-World Impact

At ASH 2025, CAR-T felt less like an experimental frontier and more like a maturing modality struggling to keep pace with its own promise. Guidelines now favor CAR-T in first-line multiple myeloma...

AI at ESMO 2025: Many Advances, Much Promise

At the ESMO Congress 2025, held last month in Berlin, AI was a frequent thread in the presented content. The event, sponsored by the European Society for Medical Oncology (ESMO), was attended...

Highlights from ESMO 2025

A summary of the most pertinent oncology data and insights presented at this year’s ESMO conference ESMO 2025 concluded last week in Berlin, marking the 50th anniversary of this important oncology congress....

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Authors: S Gupta, Y Loriot, M S Van der Heijden, J Bedke, B P Valderrama, E Kikuchi, A Fléchon, D Petrylak, M De Santis, M D Galsky, J L Lee 11, U...

Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma

Authors: A V Danilov, S K Thiruvengadam, K Linton, K Cumings, V Chirikov, A Mutebi, S B Chawla, A Chhibber, F R Navarro, F M Gonçalves, A Wang, Z Ding, A Alshreef,...

Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma

Authors: L Podger, D Serrano, L Li, L Zhan, B Tang, G Barnes Published: Journal of Patient-Reported Outcomes, 2025 View publication Background The EORTC QLQ-OES18 has previously demonstrated clinical validity; however, there...

Determining health care cost drivers in older Hodgkin lymphoma survivors using interpretable machine learning methods

Authors: Z A Siddiqui, Y P Mbous, S Nduaguba, T LeMasters, V G Scott, J S Patel, U Sambamoorthi Published: Journal of Managed Care & Specialty Pharmacy, 2025 View publication Background The...

Direct economic burden of post-cancer treatment pain among cancer survivors in the United States: A population-based retrospective longitudinal study

Authors: Y P V Mbous, R Mohamed, U Osahor, T J LeMasters Published: The International Journal of Health Planning and Management, 2025 View publication Purpose Post-cancer treatment pain (PCTP) is prevalent among...

A cost-effectiveness analysis of abemaciclib in combination with adjuvant endocrine therapy for HR+, HER2–, node-positive, high-risk early breast cancer

Authors: A Davie, S Traoré, W Badreldin, A Torstensson, E Cakar, A C McCullough, S Tempelaar, E Fenwick & P S Hall Published: Advances in Therapy, 2025 View publication Introduction The monarchE...

News